Parsing Pros And Cons Of FDA's Expedited Access Pathway
The U.S. Food and Drug Administration initiated an expedited access pathway ("EAP") program, effective April 15, 2015, for certain medical devices that are subject to premarket approval applications or de novo...To view the full article, register now.
Already a subscriber? Click here to view full article